During studies in our laboratory to search for electrophilic affinity ligands for the androgen receptor (AR), we discovered that structural modification of known non-steroidal anti-androgens results in androgenic activity. These compounds represents a new class of androgenic drugs, and were the first reported non-steroidal AR agonists. Others have recently confirmed the ability of non-steroidal ligands to stimulate AR- mediated transcription. The studies proposed herein are a pivotal extension of research in this field based on recently reported structure- activity relationships and our experience binding, pharmacology, and pharmacokinetics of non-steroidal AR ligands. Our studies are divided into three independent efforts: 1. Design and Synthesis and Novel Non-steroidal AR Ligands. We synthesized a series of bicalutamide analogs that bind the AR with high affinity and induce androgen receptor-mediated transcriptional activation. We proposed herein a strategy for rational drug design and organic syntheses of additional non-steroidal androgens based on literature data and preliminary data obtained in our laboratories. 2. In Vitro Functional Activity and Specificity for AR. We will examine AR binding affinity and AR-mediated transcriptional activation of potential non-steroidal androgens in cells transfected with the human. AR. A key element in evaluation of these drugs will be the ability to discriminate between AR and other steroid receptors, such as glucocorticoid (GR), progesterone (PR) and estrogen receptors (ER). Whole cell binding experiments and transcriptional activation studies will be conducted in cells transfected with the GR, PR., ER and AR to examine receptor specificity. 3. Androgenic and Anabolic Activity in Whole Animals. The utility of these compounds is ultimately dependent on their ability to stimulate androgen-mediated growth in whole animals. We will conduct integrated pharmacokinetic and efficacy studies in castrated and intact male rats to determine the in vivo pharmacologic activity, bioavailability, and pharmacokinetics of these drugs. The overall goal of these studies is to develop structure-activity relationships based on the physicochemical and pharmacokinetic properties of these drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
3R01DK059800-03S1
Application #
6728151
Study Section
Pharmacology A Study Section (PHRA)
Program Officer
Margolis, Ronald N
Project Start
2000-09-30
Project End
2004-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
3
Fiscal Year
2003
Total Cost
$14,750
Indirect Cost
Name
Ohio State University
Department
Type
Schools of Pharmacy
DUNS #
071650709
City
Columbus
State
OH
Country
United States
Zip Code
43210
Jones, Amanda; Hwang, Dong Jin; Duke 3rd, Charles B et al. (2010) Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Pharmacol Exp Ther 334:439-48
Li, Wei; Hwang, Dong Jin; Cremer, Dieter et al. (2009) Structure determination of chiral sulfoxide in diastereomeric bicalutamide derivatives. Chirality 21:578-83
Jones, Amanda; Chen, Jiyun; Hwang, Dong Jin et al. (2009) Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology 150:385-95
Bohl, Casey E; Wu, Zengru; Chen, Jiyun et al. (2008) Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators. Bioorg Med Chem Lett 18:5567-70
Gao, Wenqing; Dalton, James T (2007) Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today 12:241-8
Kearbey, Jeffrey D; Gao, Wenqing; Narayanan, Ramesh et al. (2007) Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res 24:328-35
Bohl, Casey E; Wu, Zengru; Miller, Duane D et al. (2007) Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem 282:13648-55
Gao, Wenqing; Dalton, James T (2007) Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase? Mol Interv 7:10-3
Gao, Wenqing; Wu, Zengru; Bohl, Casey E et al. (2006) Characterization of the in vitro metabolism of selective androgen receptor modulator using human, rat, and dog liver enzyme preparations. Drug Metab Dispos 34:243-53
Segal, Scott; Narayanan, Ramesh; Dalton, James T (2006) Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin Investig Drugs 15:377-87

Showing the most recent 10 out of 38 publications